Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Juno Therapeutics

Drug Profile

Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Juno Therapeutics

Alternative Names: Anti-interleukin13 receptor alpha-2 CAR-T cell therapy - Juno Therapeutics; CAR T cell therapy targeting IL13 receptor alpha-2 - Juno Therapeutics; IL13rα2 CAR-T cell therapy - Juno Therapeutics

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 13 Apr 2018 Juno Therapeutics plans a phase I trial for Glioblastoma in USA in 2018
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 01 Mar 2017 Preclinical trials in Glioblastoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top